Table 2. Pattern of resistance to anti-TB drugs in MDR-TB cases, the Fourth National Anti-Tuberculosis Drug Resistance Survey in Viet Nam, 2011.
| Total | New cases | Previously treated cases | ||||
|---|---|---|---|---|---|---|
| Number tested | Resistance n (%, 95% CI) |
Number tested | Resistance n (%, 95% CI) |
Number tested | Resistance n (%, 95% CI) |
|
| First-line drug | ||||||
| Ethambutol (EMB) | 91 | 50 (54.9; 44.5–65.4) | 46 | 29 (63.0; 48.6–77.5) | 45 | 21 (46.7; 31.5–61.8) |
| Streptomycin (SM) | 91 | 84 (92.3; 86.7–97.9) | 46 | 44 (95.7; 89.5–100) | 45 | 40 (88.9; 79.3–98.4) |
| Isoniazid (INH) | 91 | 91 (100) | 46 | 46 (100) | 45 | 45 (100) |
| Rifampicin (RMP) | 91 | 91 (100) | 46 | 46 (100) | 45 | 45(100) |
| Second-line drug | ||||||
| Amikacin (AM) | 84 | 1 (1.2; 0–3.6) | 41 | 0 (0) | 43 | 1 (2.3; 0–7.0) |
| Capreomycin (CM) | 84 | 5 (6.0; 0.8–11.1) | 41 | 2 (4.9; 0–11.8) | 43 | 3 (7.0; 0–14.9) |
| Kanamycin (KM) | 84 | 5 (6.0; 0.8–11.1) | 41 | 2 (4.9; 0–11.8) | 43 | 3 (7.0; 0–14.9) |
| Ofloxacin (OFX) | 84 | 15 (17.9; 9.4–26.2) | 41 | 8 (19.5; 6.8–32.1) | 43 | 7 (16.3; 4.7–27.8) |
| Pre-XDR-TB | 84 | 15 (17.9; 9.4–26.2) | 41 | 8 (19.5; 6.8–32.1) | 43 | 7 (16.3; 4.7–27.8) |
| XDR-TB | 84 | 5 (6.0; 0.8–11.1) | 41 | 2 (4.9; 0–11.8) | 43 | 3 (7.0; 0–14.9) |
| AM+CM+KM+OFX | 84 | 1 (1.2; 0–3.6) | 41 | 0 (0) | 43 | 1 (2.3; 0–7.0) |
| CM+KM+OFX | 84 | 5 (6.0; 0.8–11.1) | 41 | 2 (4.9; 0–11.8) | 43 | 3 (7.0; 0–14.9) |
CI, confidence interval; TB, tuberculosis; and XDR-TB, extensively drug-resistant tuberculosis.